Industries de la santé
22 Mars 2017
RBP-7000, a new pipeline drug developed by Indivior for the treatment of schizophrenia, has the potential to benefit patients who have previously demonstrated, or are at a high risk of, non-compliance, according to research and consulting firm GlobalData. |As explored in the company’s most recent schizophrenia report, antipsychotic products currently on the market for the treatment of...
Plus d'articles...
- Genkyotex annonce sa participation à la 1ère Conférence Investisseur H.C. Wainwright sur la NASH à New York le 3 avril 2017
- $100 billion of revenues up for grabs for drug manufacturers by 2020 as patents for key biologics expire
- La clinique Saint-George de Nice implante son 1er sternum CERAMIL®
- La responsabilité de l'hôpital envers les patients et les personnels de santé